Kaitlyn D’Onofrio

DocwireNews

Disease status as early as three and six months may predict long-term&nbsp;outcomes&nbsp;in antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) patients, a study has found.&nbsp;Researchers analyzed the&nbsp;CYCAZAREM, NORAM, MEPEX &amp; CYCLOPS&nbsp;trials&nbsp;and&nbsp;long-term registry data.&nbsp;They evaluated patients at baseline, three months, and six months for mortality and end-stage renal failure (ESRF) risks. Six-month outcomes were sustained remission (remission by three months, sustained to six months), late remission (remission after three and by six months), relapsing disease (remission by three months but relapse by six months), or refractory disease (no remission by six months).&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Analysis of disease activity in 354 patients with ANCA associated vasculitis (AAV) enrolled in 4 trials shows 13% with ESRD and 19% died. Disease activity at 3 &amp; 6 mos predicted later ESRD or death <a href="https://t.co/NZu1kJuFF2">https://t.co/NZu1kJuFF2</a>
&mdash; Dr. John Cush (@RheumNow) <a href="https://twitter.com/RheumNow/status/1062695431875018752?ref_src=twsrc%5Etfw">November 14, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>A total of 354 patients were followed for 5.7 years, of which 46 (13%) developed ESRF, 66 (18.6%) died, and 89 (25.1%) suffered either death or ESRF. At six months, late remission&nbsp;(hazard ratio [HR]&nbsp;=&nbsp;2.94&nbsp;(1.1&#8208;7.85), p&nbsp;=&nbsp;0.031), relapsing disease (HR&nbsp;=&nbsp;8.21&nbsp;(2.73&#8208;24.65), p&nbsp;=&nbsp;0.001),&nbsp;and&nbsp;refractory disease (HR&nbsp;=&nbsp;4.89&nbsp;(1.96&#8208;12.18), p&nbsp;=&nbsp;0.001)&nbsp;all were associated with significantly increased odds of the endpoints of death or ESRF. Researchers observed similar results when looking specifically at odds of death and ESRF.&nbsp;Age&nbsp;(HR = 1.02 (1&#8208;1.05)&nbsp;and estimated&nbsp;glomerular filtration rate&nbsp;(HR = 0.94 (0.92&#8208;0.95), p = 0.001)&nbsp;were also correlated with death and ESRF.&nbsp;&ldquo;This study suggests that disease status at three and six months may predict the risk of long&#8208;term mortality and ESRF in AAV, and that these time points may be valid end&#8208;points for induction trials in AAV,&rdquo; the researchers wrote. &ldquo;These results need to be validated in a larger dataset.&rdquo;&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/rituximab-polyangiitis-vasculitis-patients/">Rituximab Effectively Treats Pediatric Vasculitis Patients</a>&nbsp;<a href="https://proddocwire.wpengine.com/neurology/treatment-and-long-term-outcomes-of-primary-central-nervous-system-vasculitis-original-contributions/">Treatment and Long-Term Outcomes of Primary Central Nervous System Vasculitis</a>&nbsp;<a href="https://proddocwire.wpengine.com/cardiology/matrix-metalloprotease-9-mmp-9-producing-monocytes-enable-t-cells-to-invade-the-vessel-wall-and-cause-vasculitis-original-research/">Matrix Metalloprotease-9 (MMP-9)-Producing Monocytes Enable T Cells to Invade the Vessel Wall and Cause Vasculitis</a>&nbsp;Source:&nbsp;<a href="https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.40776">Arthritis &amp; Rheumatology</a>

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Latest News

Early Disease Management in ANCA-Associated Vasculitis Indicative of Long-term Outcomes

End-Stage Renal Disease

Disease status as early as three and six months may predict long-term outcomes in antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) patients, a study has ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe